Award
Food and Drug Administration 1R01FD008168-01A1
CD5-deleted chimeric antigen receptor cells (Senza5 CART5) to enhance immunotherapy against T cell non-Hodgkin lymphoma (NHL): a first-in-human phase I clinical trial
Recipient
University of Pennsylvania
Award Amount
$3,421,591.00
Ceiling
$3,421,591.00
Awarded
September 30, 2025
Identifier
1R01FD008168-01A1
This award funds a phase I clinical trial to test a novel CAR T-cell therapy targeting T-cell non-Hodgkin lymphoma, focusing on safety and efficacy evaluation.
Description
A first-in-human phase I clinical trial for a novel CAR T-cell therapy targeting T-cell non-Hodgkin lymphoma, funded by the FDA and conducted at the University of Pennsylvania. The project aims to evaluate safety, toxicity, and efficacy of CD5-deleted anti-CD5 CAR T-cells and includes correlative studies such as flow cytometry, single-cell transcriptomics, cytokine profiling, and digital spatial profiling.